European Cancer Information System<\/a> (ECIS).<\/p>\n\u201cWith AI and large data, thousands of slides, we have super-specialised an algorithm,\u201d Furuseth said.<\/p>\n
More accurate than human pathologists<\/p>\n
The company is a spin-out from a research collaboration between Oxford University, Oslo University Hospital in Norway, and University College London (UCL). This partnership developed the foundational research behind its AI-based prognostic technology.<\/p>\n
Domore Diagnostics claims its tool has proven to be more accurate in predicting the outcome of the patient than human pathologists. <\/p>\n
\u201cWe don’t really know what the AI is looking for. But we have afterwards correlated [AI outcomes] with pathologist evaluation and seeing that it makes sense,\u201d Andreas Kleppe, a research director at Oslo University Hospital Research, told Euronews Health.<\/p>\n
\u201cIt [the AI] picks up many of the features that pathologists also look at, but it of course also combines this and looks at things that pathologists may not know,\u201d Kleppe added.<\/p>\n
This improved accuracy can help doctors decide which patients actually need strong treatments such as chemotherapy and which patients can safely avoid them.<\/p>\n
Prognostic analysis is an important step after surgery, where the tumour has been removed, as some patients may still harbour small metastases, secondary cancer growths that spread from the original tumour.<\/p>\n
Most colorectal cancer patients are cured by surgery alone, however, chemotherapy often follows surgery as a \u201cone-size-fits-all approach,\u201d with \u201cno benefit to the majority of patients, only exposing them to short- and long-term side effects,\u201d the company said. <\/p>\n
Between 96 and 98 per cent of stage two patients and 80 per cent of stage three patients are exposed to short and long-term side effects without gaining improved outcomes, the company added.<\/p>\n
\u201cExactly understanding what represents high risk of metastasis and low risk is difficult for a human to judge because it’s so complex,\u201d Furuseth said.<\/p>\n
How does it work?<\/p>\n
DoMore Diagnostics\u2019 system is trained on thousands of images.<\/p>\n
According to Kleppe, this gives it far better judgment in identifying the high-risk features that are linked to recurrence and death from the cancer. <\/p>\n
The tool scans digital images of the same cancer tissue samples that pathologists use to look at and can tell how fast the cancer is likely to grow and how risky it is.<\/p>\n
\u201cWhen we develop the AI solutions, we feed in these images directly, and then the outcome of the patients several years after surgery,\u201d Kleppe said.<\/p>\n
\u201cAnd then we make the computer see the relationship between those. So we don’t rely on the pathologist’s evaluation directly, we just rely on the outcome,\u201d he added.<\/p>\n
This process gives doctors a more precise understanding of how aggressive a patient\u2019s cancer is, the Norwegian medical start-up said. <\/p>\n
Domore Diagnostics\u2019 colorectal-cancer test is currently used to validate prognostic analyses at hospitals in Europe, the United States, Japan, and Mexico.<\/p>\n
For more on this story, watch the video in the media player above.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"Cancer patients may soon be able to avoid or receive chemotherapy more precisely thanks to artificial intelligence (AI).…\n","protected":false},"author":2,"featured_media":233535,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[289,110,24148,18,135,19,17,610,124288,94],"class_list":{"0":"post-233534","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-artificial-intelligence","9":"tag-cancer","10":"tag-early-diagnosis","11":"tag-eire","12":"tag-health","13":"tag-ie","14":"tag-ireland","15":"tag-machine-learning","16":"tag-medical-sciences","17":"tag-treatment"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115722100912718303","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/233534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=233534"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/233534\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/233535"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=233534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=233534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=233534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}